Quick Update for DexCom (DXCM) Investors

By Ken Smith • Friday, July 26 15:07 • Permanent Link

DexCom sank -41.5% this afternoon, compared to the S&P 500's day change of 1.0%. Today's losers may turn out to be tomorrow's winners, so be sure to check the stock's fundamentals before making an investment decision:

DexCom has logged a -18.5% 52 week change, compared to 17.8% for the S&P 500
DXCM has an average analyst rating of buy and is -58.26% away from its mean target price of $151.17 per share
Its trailing earnings per share (EPS) is $1.61, which brings its trailing Price to Earnings (P/E) ratio to 39.2. The Health Care sector's average P/E ratio is 27.61
The company's forward earnings per share (EPS) is $2.25 and its forward P/E ratio is 28.0
The company has a Price to Book (P/B) ratio of 10.39 in contrast to the Health Care sector's average P/B ratio is 3.69
The current ratio is currently 2.8, which consists in its liquid assets divided by any liabilities due within in the next 12 months
DXCM has reported YOY quarterly earnings growth of 26.2% and gross profit margins of 0.6%
The company's free cash flow for the last fiscal year was $511.9 Million and the average free cash flow growth rate is 40.0%
DexCom's revenues have an average growth rate of 23.6% with operating expenses growing at 15.6%. The company's current operating margins stand at 16.5%

The above analysis is intended for educational purposes only and was performed on the basis of publicly available data. It is not to be construed as a recommendation to buy or sell any security. Any buy, sell, or other recommendations mentioned in the article are direct quotations of consensus recommendations from the analysts covering the stock, and do not represent the opinions of Market Inference or its writers. Past performance, accounting data, and inferences about market position and corporate valuation are not reliable indicators of future price movements. Market Inference does not provide financial advice. Investors should conduct their own review and analysis of any company of interest before making an investment decision.